PARIS – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reported that its 12-lipoxygenase inhibitor CAD-1005 reduced new or worsening thrombotic events by more than 25 percentage points versus placebo in a Phase 2 trial in heparin-induced thrombocytopenia (HIT), with 50% of treated patients affected versus more than 75% on placebo. The data were presented as one of three late-breaking abstracts at the ISTH 2026 Congress in Paris.
Trial is first randomized, blinded, placebo-controlled study in HIT
Principal Investigator Dr. Steven E. McKenzie delivered the oral presentation, which Cadrenal describes as the first randomized, blinded, placebo-controlled trial in HIT patients. CAD-1005 was formerly known as VLX-1005. The study was not sufficiently powered for statistical significance.
No serious adverse events, major bleeding or deaths reported
Cadrenal reported no serious adverse events attributable to CAD-1005, no major bleeding in SRA+ patients and no deaths. Treatment was associated with fewer thromboembolic events without an increase in major bleeding. CAD-1005 was tested as an add-on to standard anticoagulation.
Platelet count recovery proves inadequate as efficacy surrogate
Thrombotic events continued after platelet counts recovered, according to the company. Cadrenal says this finding will shape the design of its pivotal Phase 3 registration trial. Standard non-heparin anticoagulants reduce thrombin generation but do not address antibody-mediated platelet activation. CAD-1005 is designed to block the 12-LOX immune signaling loop behind that activation.
ISTH 2026 draws 6,000 registrants and 3,100 abstracts
The congress drew the largest in-person audience in more than a decade, with over 6,000 registrants and more than 3,100 abstract submissions. The late-breaking program is reserved for high-impact clinical trial results and first disclosures.
Cadrenal sizes peak sales at $2 billion and pursues partnering
Cadrenal estimates peak annual revenue of $2 billion for CAD-1005 and says no root-cause therapies are currently approved for HIT. The compound holds U.S. FDA Orphan Drug and Fast Track designations and European Medicines Agency orphan drug status.
CEO Quang X. Pham said that following the company's recent financing, Cadrenal is "well-positioned to advance partnering opportunities" for CAD-1005 and tecarfarin, its late-stage oral vitamin K antagonist. The company cites partnership, capital-raising and Phase 3 design and execution as risks to its plans, including the path to an NDA submission.